Physician profile
Jawad Vaid
NPI 1750600029
$1,168.24
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $271 · 2020: $172 · 2021: $395 · 2022: $193 · 2023: $111 · 2024: $25.46.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $137.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $136.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $331.21 | 2019-2023 | Briviact |
| E.R. Squibb & Sons, L.L.C. | $114.55 | 2019-2023 | Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $112.98 | 2019-2023 | Spiriva Respimat, Stiolto Respimat |
| Janssen Pharmaceuticals, INC | $104.62 | 2019-2022 | |
| Gilead Sciences, INC. | $98.01 | 2021-2023 | |
| Pfizer INC. | $65.60 | 2020-2021 | |
| Allergan, INC. | $54.51 | 2019 | |
| Melinta Therapeutics, LLC | $46.08 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $42.34 | 2019 | |
| Abbvie INC. | $36.25 | 2022-2023 | Teflaro |
| Paratek Pharmaceuticals, INC. | $29.52 | 2021-2022 | |
| Smith+Nephew, INC. | $25.46 | 2024 | Collagenase Santyl |
| Merck Sharp & Dohme LLC | $24.93 | 2021 | |
| Novo Nordisk INC | $21.56 | 2019 | |
| Advanced Respiratory, INC | $15.59 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $15.39 | 2020 | |
| Ferring Pharmaceuticals INC. | $14.86 | 2022 | |
| Nestle Healthcare Nutrition INC. | $14.78 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jawad Vaid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.